MiRNAs in gastrointestinal diseases: Can we effectively deliver RNA-based therapeutics orally?

A. K.M. Nawshad Hossian, Gerardo G. MacKenzie, George Mattheolabakis

Research output: Contribution to journalReview articlepeer-review

7 Scopus citations


Nucleic acid-based therapeutics are evaluated for their potential of treating a plethora of diseases, including cancer and inflammation. Short nucleic acids, such as miRNAs, have emerged as versatile regulators for gene expression and are studied for therapeutic purposes. However, their inherent instability in vivo following enteral and parenteral administration has prompted the development of novel methodologies for their delivery. Although research on the oral delivery of siRNAs is progressing, with the development and utilization of promising carrier-based methodologies for the treatment of a plethora of gastrointestinal diseases, research on miRNA-based oral therapeutics is lagging behind. In this review, we present the potential role of miRNAs in diseases of the GI tract, and analyze current research and the cardinal features of the novel carrier systems used for nucleic acid oral delivery that can be expanded for oral miRNA administration.

Original languageEnglish (US)
Pages (from-to)2873-2889
Number of pages17
Issue number21
StatePublished - Jan 1 2019
Externally publishedYes


  • delivery
  • miRNA therapeutics
  • non-viral vectors
  • oral delivery

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)


Dive into the research topics of 'MiRNAs in gastrointestinal diseases: Can we effectively deliver RNA-based therapeutics orally?'. Together they form a unique fingerprint.

Cite this